Introduction: Clinical history, symptoms, lab parameter along with radiological investigation help in the diagnosis and management of spondyloarthritis (SpA). However, spondyloarthritis manage mainly by NSAIDs.NSAIDs can cause subclinical renal injury which is not manifest in routine renal function tests (like serum creatinine). Published case series among ankylosing spondylitis patients have shown the prevalence of renal complication 72% higher than the general population. A limited number of studies are present on evaluating the effect of NSAIDs on changes in the level of cystatin-c. So here we studied the change in parameters of serum creatinine and cystatin-c level after the use of NSAIDs in the setting of SpA. Objective: To study the relation of the duration of use of NSAIDs in Spondyloarthritis patients and the incidence of subclinical kidney injury by comparing serum creatinine with serum cystatin-c. Methods: A hospital-based prospective observational study carried out over one year in IMS and SUM hospital over 31 patients on spondyloarthritis patients. Where the level of serum creatinine and cystatin-c level calculated on the baseline, four weeks and twelve-week. Results: Patients using a different type of NSAIDs there is no significant change in serum creatinine value (p=0.546).while a significant change in serum cystatin-c level (p__ampersandsignlt;0.012) was observed over twelve weeks Conclusion: There is no significant change in serum creatinine value after intake of NSAIDs.while significant change in serum cystatin-c value which increases two or three-fold higher than initial value and therefore it is concluded that serum cystatin-c can be used as an early biomarker for subclinical kidney injury than serum creatinine.